AI reads CT scans to match kidney cancer patients with targeted drug
NCT ID NCT07332923
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 500 kidney cancer patients to see if CT scans and machine learning can predict levels of a protein called HIF-2α. The goal is to better identify which patients might benefit from a targeted drug called Belzutifan, reducing unnecessary treatments and improving outcomes. The research is observational and does not test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
first hospital affiliated of Fujian medical university
Fuzhou, Fujian, 350005, China